What this is
- How it works
- Makes the kidneys flush extra sugar and salt into the urine. Started as a diabetes drug; now also used for heart and kidney disease.-gliflozin: sodium-glucose co-transporter inhibitors WHO name stem
- How it’s given
- “Ertugliflozin 5/15mg once daily in addition to standard of care”In the company’s words, NCT05644717 on ClinicalTrials.gov
- Tested for
- Liver Fat, Liver Fibrosis, Glycemic Control, Body Weight Changes, Waist Circumference, Tolerance
- Main trialPhase 4
- “Open-label, prospective, single-arm, multicenter study to determine effects of Ertugliflozin on liver fat, liver fibrosis \& glycemic control in subjects with Type 2 Diabetes Mellitus (T2DM) with Non-Alcoholic Fatty Liver Disease (NAFLD)/Non-Alcoholic Steatohepatitis (NASH)”In the company’s words, NCT05644717 on ClinicalTrials.gov
- Other names
- 15mg
Other drugs for Liver Fibrosis
- ElafibranorIpsen · Phase 3
- ResmetiromMadrigal Pharmaceuticals · Phase 3
- Saroglitazar MagnesiumZydus Therapeutics Inc. · Phase 3
- HydronidoneBeijing Continent Pharmaceutical Co, Ltd. · Phase 3
- LinerixibatGSK · Phase 3
- SeladelparGilead (Kite) · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Recruiting | 1 Nov 2025 | Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD | |
| Phase 4Ended | not given | DiEtary Sodium Intake effects on ertugliflozin-induced changes in GFR, reNal oxygenation and systemic hemodynamics: the DESIGN study, a randomized, placebo-controlled, cross-over study with ertugliflozin in people with type 2 diabetes. | |
| Phase 4Ended | not given | SGLT-2i, Heart, Improvement of Cardiovascular Autonomic Neuropathy |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026